Dr. Om Alkhair Aboelkhair
panellist
Consultant, Hematology/Oncology, Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia
Consultant, Adult Oncology, Department of Oncology, Specialized Medical Center Hospital, Riyadh, Saudi Arabia
Consultant, Adult Oncology, Department of Oncology, King Abdulaziz Medical City - NGHA, Riyadh, Saudi Arabia
09:45 –10:30
Friday 3-5-2024 Day 1
Role of anthracyclines in early breast cancer
- When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer
When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer
Moderator:
Dr. Meteeb Alfohaidi
Panel:
15:00-15:45
Friday 3-5-2024 Day 1
Genomic tools in breast cancer
- chemotherapy in high risk lobular/mucinous BC?
- Neoadjuvant therapy in premenopausal patients with lobular BC?
Adjuvant therapy with node negative and node positive lobular BC?
Adjuvant therapy in luminal BC with RS 16-25?
Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours?? - Oncotype DX and selection of neoadjuvant hormonal vs chemotherapy therapy
- Role of interval Ki67 assessment with neoadjuvant hormonal therapy
Moderator: 
Ahmed Alshehri
Panel:
